– USA, CA – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Dr. Gregory Reyes, M.D., Ph.D. to its Board of Directors, effective November 30, 2020.
“Dr. Reyes’ expert role and track record in taking small molecules and biologics through the development process make him an ideal addition for the next phase of Artelo’s advancement,” said Board Chair, Connie Matsui. “We are grateful and excited to welcome him to the Board.”
About Dr. Gregory Reyes
Dr. Reyes, a drug discovery and development veteran brings 35 years of experience in biotech and large pharma to Artelo. Currently, he is co-founder and Board member of San Diego-based Orox Biosciences. Previously, he was SVP, Drug Discovery & Site Head at Celgene San Diego, led the Oncology franchise at Biogen Idec, headed Discovery Biology at the Pfizer Ann Arbor campus, and oversaw Tumor Biology and Infectious Diseases at Schering-Plough Research Institute. Over the course of his career, Dr. Reyes and his teams advanced more than 50 small molecules and biologics from discovery into preclinical and clinical development. One of these was Merck’s Victrelis which was approved as one of the first small-molecule antiviral treatments for chronic hepatitis C and which received the 2012 Prix Galien Award along with Vertex’s Incivek as the ‘best pharmaceutical agent’ in both the UK and US.
“As a young company, Artelo has demonstrated impressive versatility and progress in identifying and developing potentially transformative treatments in cancer, anorexia, and anxiety disorders,” said Dr. Reyes. “I’m looking forward to joining this seasoned team and providing guidance for the growth and development of the company and its product candidates.”
Dr. Reyes obtained his M.D. and Ph.D. degrees through the Medical Scientist Training Program at The Johns Hopkins School of Medicine. He completed his medical and postdoctoral training at Stanford University Hospital, where he was awarded a Damon Runyon Cancer Research Fellowship for studies at Stanford’s Cancer Biology Research Lab. He has nearly 100 scientific publications and 50 US and foreign patents and applications. Dr. Reyes currently serves as an advisor to Cancer Research UK’s New Agents Committee and previously served on NIH’s National Advisory General Medical Sciences Council, and the Standing Review Committee for the Research Centers in Minority Institutions, National Center for Research Resources.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies.
For more information: https://artelobio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.